CSRxP ANALYSIS: BIG PHARMA’S PROFIT MARGINS CLIMB TO 11 TIMES GREATER THAN OTHER SECTORS IN DRUG SUPPLY CHAIN
Jul 27, 2026
Brand Name Drug Companies Banking Ever Higher Profits Fueled by Egregious… Read More
© 2026 CSRXP- All Rights Reserved
Updates
BIG PHARMA EARNINGS WATCH: NOVARTIS & ROCHE
Jul 27, 2026
Big Pharma Giants Continue Topping Wall Street Expectations Following Price… Read More
CSRxP APPLAUDS GROWING BIPARTISAN MOMENTUM TO LOWER PRESCRIPTION DRUG PRICES FOR AMERICAN CONSUMERS BY FOSTERING GREATER COMPETITION
Jul 23, 2026
Both Chambers of Congress and Lawmakers in Both Parties Advance Market-Based… Read More
CSRxP: SENATE HELP COMMITTEE CAN BUILD ON BIPARTISAN MOMENTUM TO BOOST COMPETITION AND LOWER DRUG PRICES
Jul 21, 2026
Lawmakers Have Opportunity to Build On Recent Positive Work to Lower Drug… Read More
CSRxP ENCOURAGES U.S. HOUSE ENERGY & COMMERCE COMMITTEE TO ADVANCE BIPARTISAN SOLUTIONS TO PROMOTE BIOSIMILAR COMPETITION, LOWER DRUG PRICES
Jul 20, 2026
Lawmakers Can Bring More Affordable Alternatives for American Consumers to… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Jul 17, 2026
Johnson & Johnson Tops Profit Expectations, Lifts Outlook Following Price… Read More
CSRxP: SENATE JUDICIARY COMMITTEE MUST REJECT BIG PHARMA’S FALSE RHETORIC ON INNOVATION, HOLD BRAND NAME MANUFACTURERS ACCOUNTABLE FOR PATENT ABUSE
Jul 13, 2026
Big Pharma’s Anti-Competitive Tactics That Extend Monopolies Are… Read More
DOSE OF REALITY: REPORT FINDS BIG PHARMA CONTINUES TO SET OUT-OF-CONTROL LAUNCH PRICES ON NEW MEDICINES COMING TO MARKET
Jul 2, 2026
Reuters Analysis Finds Average Launch Price For Drugs Approved By FDA in 2025… Read More
THEY SAID IT! LAWMAKERS HIGHLIGHT IMPORTANCE OF GREATER COMPETITION TO LOWER PRESCRIPTION DRUG PRICES AT U.S. SENATE HELP COMMITTEE MARKUP
Jun 18, 2026
Lawmakers Advance Bipartisan Solutions to Hold Big Pharma Accountable for… Read More
CSRxP COMMENDS U.S. SENATE HELP COMMITTEE FOR PASSING BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES
Jun 17, 2026
Committee Markup Advances Solutions to Crack Down on Big Pharma’s Patent… Read More
SECOND OPINION: CLOSING LOOPHOLES BIG PHARMA EXPLOITS TO BLOCK COMPETITION AND KEEP DRUG PRICES HIGH WILL NOT UNDERMINE INNOVATION
Jun 16, 2026
Big Pharma’s Arguments Against Bipartisan, Market-Based Solutions to Foster… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY FOSTERING GREATER COMPETITION
Jun 16, 2026
Lawmakers Should Advance Biosimilar Red Tape Elimination Act, Medication… Read More